Bulimia Nervosa Market Therapeutics Assessment Report 2019: Market Size, Share Reach at $ 1.1 billion by 2023
Bulimia Nervosa Market – Overview
The incidence of eating disorders in the society have risen sharply especially cases related to bulimia nervosa. Market reports associated to the pharmaceutical industry have been made accessible by Market Research Future which creates reports on other industry verticals that summaries the current market scenarios. The market is predicted to surge at a CAGR of 4.5% approximately in the upcoming forecast period.
The cases for bulimia nervosa have been on the risen chiefly due to factors such as unrealistic body type expectations, increased peer pressure coupled with the rise in alcoholism. The market is anticipated to observe a renewed growth surge primarily due to the rise in research towards the treatment of the disorder and launch of drugs that are increasingly effective in counteracting the symptoms of the disorder.
Get Sample Report@ https://www.marketresearchfuture.com/sample_request/1417
Detailed Regional Analysis
The regional analysis of the bulimia nervosa market spans across regions such as North America, Europe, Asia Pacific, Africa, and the Middle East. Globally, the bulimia nervosa market is directed by the North American region. Due to the growing incident of bulimia nervosa in the North American region, the market has grown extensively. The European region has the next major market for the bulimia nervosa market because of the governmental support and a well-developed healthcare sector. The Asia Pacific region is anticipated to develop at the quickest rate owing to an enormous population base in this region.
Competitive Analysis
The market has significantly counterbalanced the market advantages and thus is encouraging an upsurge in the number of firms in the market. The modification of the product range in the market is growing the opportunity for the progress of the market. The capacity to utilize the economies of scale is additionally proving to be beneficial for comprehensive market growth. The market is at an optimally beneficial level and will be capable of generating better value for the firms in the market and its shareholders. The management propensities in the market are strengthening the level of growth that can be achieved in the current market scenario. The growth patterns are revised in tandem to the customer likings to realize the greatest growth, and in the long run, viability.
The major contenders in the bulimia nervosa market are Stryker (U.S), Philips Healthcare (U.S), Abbott (U.S), Siemens Healthcare GmbH (Germany), General Electric Company (U.K), Johnson & Johnson Services, Inc. (U.S), Covidien Ltd(Ireland) and Penumbra, Inc. (U.S) to name a few.
Segmental Analysis
The segmentation of the bulimia nervosa market globally is carried out on the basis of treatment and region. The market is further segmented into the type of treatment into drug therapy, psychotherapy, and other. The psychotherapy is further sub-segmented into maudsley family therapy and other. The drug therapy is further sub-segmented into antidepressants and other. The regions counted in the market are North America, Europe, Asia Pacific, Africa, and the Middle East.
Browse Complete Report@ https://www.marketresearchfuture.com/reports/bulimia-nervosa-market-1417
Industry Updates:
Nov 2018 Opiant Pharmaceuticals, Inc., who is in the process of developing pharmacological treatments for addictions and drug overdose, recently announced that the Last Patient, Last Visit (LPLV) occurred on 2 Nov in its Phase 2 clinical trial of OPNT001, a naloxone nasal spray, for the management of Bulimia Nervosa. The rapid concentration profile of OPNT001 has the latent to deal with the unique needs of patients with Bulimia Nervosa, specifically, because it permits on-demand dosing, enabling patients to regain control of their disease.
Oct 2018 Apple is contributing 1000 Apple Watch units for a study that attempts to discover out the reasons and the symptoms for disorders such as binge eating. The disorder is medically known as Bulimia Nervosa. The analysis is being conducted by the University Of North Carolina School Of Medicine and is called Binge Eating Genetics Initiative (BEGIN).
Intended Audience
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar, Pune
+1 646 845 9312
Email: sales@marketresearchfuture.com
The incidence of eating disorders in the society have risen sharply especially cases related to bulimia nervosa. Market reports associated to the pharmaceutical industry have been made accessible by Market Research Future which creates reports on other industry verticals that summaries the current market scenarios. The market is predicted to surge at a CAGR of 4.5% approximately in the upcoming forecast period.
The cases for bulimia nervosa have been on the risen chiefly due to factors such as unrealistic body type expectations, increased peer pressure coupled with the rise in alcoholism. The market is anticipated to observe a renewed growth surge primarily due to the rise in research towards the treatment of the disorder and launch of drugs that are increasingly effective in counteracting the symptoms of the disorder.
Get Sample Report@ https://www.marketresearchfuture.com/sample_request/1417
Detailed Regional Analysis
The regional analysis of the bulimia nervosa market spans across regions such as North America, Europe, Asia Pacific, Africa, and the Middle East. Globally, the bulimia nervosa market is directed by the North American region. Due to the growing incident of bulimia nervosa in the North American region, the market has grown extensively. The European region has the next major market for the bulimia nervosa market because of the governmental support and a well-developed healthcare sector. The Asia Pacific region is anticipated to develop at the quickest rate owing to an enormous population base in this region.
Competitive Analysis
The market has significantly counterbalanced the market advantages and thus is encouraging an upsurge in the number of firms in the market. The modification of the product range in the market is growing the opportunity for the progress of the market. The capacity to utilize the economies of scale is additionally proving to be beneficial for comprehensive market growth. The market is at an optimally beneficial level and will be capable of generating better value for the firms in the market and its shareholders. The management propensities in the market are strengthening the level of growth that can be achieved in the current market scenario. The growth patterns are revised in tandem to the customer likings to realize the greatest growth, and in the long run, viability.
The major contenders in the bulimia nervosa market are Stryker (U.S), Philips Healthcare (U.S), Abbott (U.S), Siemens Healthcare GmbH (Germany), General Electric Company (U.K), Johnson & Johnson Services, Inc. (U.S), Covidien Ltd(Ireland) and Penumbra, Inc. (U.S) to name a few.
Segmental Analysis
The segmentation of the bulimia nervosa market globally is carried out on the basis of treatment and region. The market is further segmented into the type of treatment into drug therapy, psychotherapy, and other. The psychotherapy is further sub-segmented into maudsley family therapy and other. The drug therapy is further sub-segmented into antidepressants and other. The regions counted in the market are North America, Europe, Asia Pacific, Africa, and the Middle East.
Browse Complete Report@ https://www.marketresearchfuture.com/reports/bulimia-nervosa-market-1417
Industry Updates:
Nov 2018 Opiant Pharmaceuticals, Inc., who is in the process of developing pharmacological treatments for addictions and drug overdose, recently announced that the Last Patient, Last Visit (LPLV) occurred on 2 Nov in its Phase 2 clinical trial of OPNT001, a naloxone nasal spray, for the management of Bulimia Nervosa. The rapid concentration profile of OPNT001 has the latent to deal with the unique needs of patients with Bulimia Nervosa, specifically, because it permits on-demand dosing, enabling patients to regain control of their disease.
Oct 2018 Apple is contributing 1000 Apple Watch units for a study that attempts to discover out the reasons and the symptoms for disorders such as binge eating. The disorder is medically known as Bulimia Nervosa. The analysis is being conducted by the University Of North Carolina School Of Medicine and is called Binge Eating Genetics Initiative (BEGIN).
Intended Audience
- Pharmaceutical companies
- Bulimia Nervosa treatment centers
- Research and Development (R&D) Companies
- Government and Independent Research Laboratories
- Contract Research Organizations (CROs)
- Medical Research Laboratories
- Academic Medical Institutes and Universities
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar, Pune
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment